Replies to post #221632 on Biotech Values

[jbog]

What % of GILD’s $98M QoQ decline in 3Q18 HCV sales was due to each of the following: a) Fewer HCV patients treated; b) Lower ASP; c) Loss of market share to Mavyret?

Any answer ties back to Abbvie and how they ruined the market for everyone, including themselves.